Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003624 · ClinicalTrials.gov registry record · Phase 2
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00003624 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group.
The verdict
NCT00003624, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in reducing the risk of side effects caused by cisplatin and paclitaxel in treating women who have ovarian, peritoneal, cervical, fallopian tube, uterine, or endometrial cancer.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003624
The ClinicalTrials.gov registry entry for NCT00003624 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00003624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003624 about?
NCT00003624 is a clinical study titled "Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in redu...
What is the current status of trial NCT00003624?
This trial is currently terminated. It is a Phase 2 study. The study started on 1998-12.
What interventions are being tested in trial NCT00003624?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003624?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.